Genomic Biomarkers of Cancer
$608,246ZIAFY2025CANIH
Division Of Basic Sciences - Nci
Investigators
Linked publications & trials
Paper 39014393Paper 38500181Paper 37474126Paper 37432627Paper 37345354Paper 37218333Paper 37164978Paper 37119018Paper 37093270Paper 37075315Paper 36964296Paper 36933012Paper 36840836Paper 36802047Paper 36655517Paper 35921407Paper 35849035Paper 35762249Paper 35649412Paper 35635863Paper 35587280Paper 35567606Paper 35501486Paper 35474866Paper 35440587Paper 35385572Paper 35357904Paper 35275197Paper 35175291Paper 35144680Paper 35103816Paper 35053576Paper 35012690Paper 34910220Paper 34736341Paper 34614192Paper 34555175Paper 33857424Paper 33112994Paper 33025139Paper 32642676Paper 32641156Paper 32572265Paper 32502305Paper 32348734Paper 32029440Paper 31996992Paper 31099395Paper 31095693Paper 31038238Paper 30259105
Abstract
We have made substantial progress on goal #3, where we have submitted a paper to Lancet Oncology, showing that molecular genomic alterations can be predicted from histopathology in CNS tumors. Our model integrates three distinct components: the first classifies CNS tumors directly from slide images ('direct model'), the second initially generates predictions for DNA methylation beta values, which are subsequently used for tumor classification ('indirect model'), and the third classifies tumor types directly from routinely available patient demographics. We can classify CNS tumors accurately and this has implications for tumor diagnostics.
View original record on NIH RePORTER →